AcoArt Orchid® & Dhalia®
膝上药物涂层球囊扩张导管
膝上药物涂层球囊扩张导管
· 提供20-300mm各种规格产品,300mm规格独家所有,为长病变患者提供治疗优选
· 亲脂载药基质+紫杉醇,提高药物转载率,优化药物传输
独有的药物涂层技术
AcoArt 药物涂层球囊使用了稳定的天然载药基质--硬脂酸镁作为药物载体,且应用了独有的紫杉醇涂层工艺,显著降低药物球囊在血管输送中的药物脱落
数据出处:先瑞达委托第三方实验室测试结果
最全的球囊尺寸分布,优化尺寸选择
导管直径覆盖3mm至12mm,首创半号直径尺寸DCB,长度覆盖20mm至300mm,远长于同类产品
既针对病变情况提供了最优化的选择,也提高了卫生经济效益
入组复杂病变,平均病变长度近15cm,超过一半的CTO患者
1. Chen Zhong,Guo Wei,Jiang Weiliang et al. IN.PACT SFA Clinical Study Using the IN.PACT Admiral Drug-Coated Balloon in a Chinese Patient Population.[J] .J Endovasc Ther, 2019, 26: 471-478.
2. Rosenfield Kenneth,Jaff Michael R,White Christopher J et al. Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease.[J] .N Engl J Med, 2015, 373: 145-53.
3. Presented by Prof. Changwei Liu @ CEC 2018. 4. Presented by Prof. Changwei Liu @ CEC 2019. 5. Presented by Prof. Jian Dong @ CEC 2021.
6个月晚期管腔丢失DCB组仅0.05mm,显示出更卓越的疗效
数据来源: Acotec Drug-Coated Balloon Catheter Randomized, Multicenter, Controlled Clinical Study in Femoropopliteal Arteries: Evidence From the AcoArt I Trial,JACC Cardiovasc Interv. 2016 Sep 26;9(18):1941-9.
24个月结果表明DCB的通畅率远高于PTA
数据来源:Drug-Coated Balloon Angioplasty Compared With Uncoated Balloons in the Treatment of 200 Chinese Patients With Severe Femoropopliteal Lesions: 24-Month Results of AcoArt I,JACC Cardiovasc Interv. 2018 Dec 10;11(23):2347-2353.
5年长期结果显示DCB的远期安全性高于PTA
数据来源:Long-term safety and efficacy of angioplasty of femoropopliteal artery disease with drug-coated balloons from the AcoArt I trial,J Vasc Surg. 2021 Sep;74(3):756-762.e3.
产品名 | AcoArt Orchid® | AcoArt Dhalia® |
药物 | 紫杉醇 | 紫杉醇 |
赋形剂 | 硬脂酸镁(亲脂性) | 硬脂酸镁(亲脂性) |
直径(mm) | 3/3.5/4/4.5/5/5.5/6/7/8/9/10/12 | 2/2.5/3/3.5/4/4.5/5/5.5/6/7/8/9/10/12 |
长度(mm) | 20/30/40/60/80/100/120/150/200/250/300 | 20/30/40/60/80/100/120/150/200/250/300 |
配用导丝(inch) | 0.035 | 0.018 |
配用鞘(F) | 5-8 | 4-8 |
标称压力(Bar) | 6 | 6 |
爆破压(Bar) | 最高18 | 最高18 |
Copyright © 2023 先瑞达医疗科技控股有限公司 京ICP备19054161号-2 MINETHINK